<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>International Biotechnology Trust Plc — News on 6ix</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc</link>
<description>Latest news and press releases for International Biotechnology Trust Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 10 Apr 2026 15:40:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/international-biotechnology-trust-plc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835e57978dffbe2df1282c4.webp</url>
<title>International Biotechnology Trust Plc</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc</link>
</image>
<item>
<title>Compliance with Market Abuse Regulation</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/compliance-with-market-abuse-regulation-53</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/compliance-with-market-abuse-regulation-53</guid>
<pubDate>Fri, 10 Apr 2026 15:40:00 GMT</pubDate>
<description>International Biotechnology Trust PLC has confirmed compliance with Market Abuse Regulation (MAR) by stating that all inside information leading up to the announcement of its six-month results for the period ending 28 February 2026 will be disseminated via a regulatory information service. This ensures the company is not prohibited from dealing in its own securities during the mandatory closed period, which is expected to end around 12 May 2026 with the publication of the results. The company ha</description>
</item>
<item>
<title>Net Asset Value(s)</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/net-asset-values-918</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/net-asset-values-918</guid>
<pubDate>Thu, 09 Apr 2026 10:32:00 GMT</pubDate>
<description>Net Asset Value(s).</description>
</item>
<item>
<title>Transaction in Own Shares</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/transaction-in-own-shares-687</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/transaction-in-own-shares-687</guid>
<pubDate>Tue, 07 Apr 2026 16:15:00 GMT</pubDate>
<description>International Biotechnology Trust plc has purchased 15,000 of its ordinary shares at 940.1 pence each, totaling £141,015, to be held in treasury. Following this transaction, the Company's issued share capital comprises 41,383,817 ordinary shares, with 9,555,983 shares now held in treasury, resulting in a total of 31,827,834 voting rights. This updated figure serves as the denominator for shareholders calculating their notification requirements under the FCA's Disclosure Guidance and Transparency</description>
</item>
<item>
<title>IBT portfolio company Apellis acquired by Biogen</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/ibt-portfolio-company-apellis-acquired-by-biogen</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/ibt-portfolio-company-apellis-acquired-by-biogen</guid>
<pubDate>Tue, 31 Mar 2026 13:55:00 GMT</pubDate>
<description>International Biotechnology Trust PLC (IBT) announced that its portfolio company, Apellis Pharmaceuticals, has agreed to be acquired by Biogen for approximately $5.6 billion, with Apellis shareholders to receive $41 per share in cash, representing a 140% premium. Apellis, which has two approved drugs, Empaveli and Syfovre, represented 2.5% of IBT's Net Asset Value as of March 30th. IBT's portfolio managers highlighted this as the third acquisition from their portfolio in March, underscoring the </description>
</item>
<item>
<title>IBT portfolio company Terns acquired by Merck</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/ibt-portfolio-company-terns-acquired-by-merck</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/ibt-portfolio-company-terns-acquired-by-merck</guid>
<pubDate>Wed, 25 Mar 2026 14:43:00 GMT</pubDate>
<description>International Biotechnology Trust PLC (IBT) announced that its portfolio company, Terns Pharmaceuticals, has agreed to be acquired by Merck for up to $6.7 billion. Terns Pharmaceuticals, a clinical-stage oncology company with its lead candidate TERN-701 in trials for chronic myeloid leukaemia, represented 3.64% of IBT's Net Asset Value as of March 24th. IBT's initial investment in Terns in March 2025 at approximately $3 per share has yielded a return multiple of approximately 17.7x. The acquisit</description>
</item>
<item>
<title>Kepler Trust Intelligence: New Research</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/kepler-trust-intelligence-new-research-92</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/kepler-trust-intelligence-new-research-92</guid>
<pubDate>Thu, 12 Mar 2026 07:00:00 GMT</pubDate>
<description>International Biotechnology Trust PLC has been highlighted as the top-performing biotech trust under its current management team over the past five years, with Kepler Trust Intelligence releasing new research for long-term investors. This research, available to UK investors, provides a comprehensive overview of the trust. Investors are reminded that past performance is not indicative of future results and the value of investments can fluctuate.
Disclaimer*</description>
</item>
<item>
<title>Portfolio company Day One acquired by Servier</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/portfolio-company-day-one-acquired-by-servier</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/portfolio-company-day-one-acquired-by-servier</guid>
<pubDate>Mon, 09 Mar 2026 08:42:00 GMT</pubDate>
<description>International Biotechnology Trust PLC announced that its portfolio company, Day One Biopharmaceuticals, has agreed to be acquired by Servier for $2.5 billion in cash, with Day One shareholders receiving $21.50 per share, a 67% premium. Day One, which represents 1.8% of IBT's Net Asset Value as of March 5th, has developed the FDA-approved OJEMDA therapy for a specific type of childhood brain tumor. This acquisition is the first for IBT in 2026 and follows nine portfolio company acquisitions in 20</description>
</item>
<item>
<title>Restatement of Net Asset Value(s)</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/restatement-of-net-asset-values</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/restatement-of-net-asset-values</guid>
<pubDate>Tue, 10 Feb 2026 12:02:00 GMT</pubDate>
<description>International Biotechnology Trust PLC has restated its unaudited cum income net asset value per share for several dates between December 29, 2025, and January 19, 2026, due to an administrative error concerning the non-accrual of an interim dividend. For example, the published NAV per share on December 29, 2025, was 1021.50, which has been revised to 1005.87. Similarly, the NAV on January 19, 2026, was revised from 1009.70 to 994.04. The company's service providers have implemented corrective me</description>
</item>
<item>
<title>Virtual Outlook Presentation</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/virtual-outlook-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/virtual-outlook-presentation</guid>
<pubDate>Fri, 06 Feb 2026 12:13:00 GMT</pubDate>
<description>International Biotechnology Trust PLC announced that portfolio managers Ailsa Craig and Marek Poszepczynski will host a virtual presentation on February 10, 2026, at 09:00 to discuss the outlook for the biotechnology sector in 2026. The presentation is open to all audiences, and questions can be submitted during the event.
Disclaimer*</description>
</item>
<item>
<title>QuotedData's In The HotSeat Special</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/quoteddatas-in-the-hotseat-special-20</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/quoteddatas-in-the-hotseat-special-20</guid>
<pubDate>Thu, 29 Jan 2026 17:26:00 GMT</pubDate>
<description>Intl. Biotechnology Trust PLC is participating in QuotedData's "In the HotSeat Special" webinar on January 30, 2026, at 11 am. Marek Poszepczynski will join a panel discussion focused on income funds for ISAs, alongside representatives from Invesco Bond Income Plus and Aberdeen Equity Income Trust. The webinar will cover weekly news from the investment companies sector and offer attendees the opportunity to ask questions.
Disclaimer*</description>
</item>
<item>
<title>Director/PDMR Shareholding</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/directorpdmr-shareholding-891</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/directorpdmr-shareholding-891</guid>
<pubDate>Wed, 28 Jan 2026 14:06:00 GMT</pubDate>
<description>Alexa Henderson, a Director at International Biotechnology Trust plc, has made an initial notification regarding a share purchase through a non-discretionary dividend reinvestment programme. On 27 January 2026, 115 ordinary shares of 25 pence each were purchased on the London Stock Exchange at a price of £9.639 per share, resulting in an aggregated transaction value of £1,108.49.
Disclaimer*</description>
</item>
<item>
<title>Block listing Interim Review</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/block-listing-interim-review-288</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/block-listing-interim-review-288</guid>
<pubDate>Mon, 05 Jan 2026 16:52:00 GMT</pubDate>
<description>International Biotechnology Trust plc has reported a block listing return for general business purposes covering the period from July 4, 2025, to January 5, 2026. The company's balance of unallotted securities under its block scheme remained unchanged at 4,712,694, as no new securities were added to the scheme and no securities were issued or allotted during this six-month period.
Disclaimer*</description>
</item>
<item>
<title>Dividend Declaration</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/dividend-declaration-441</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/dividend-declaration-441</guid>
<pubDate>Mon, 15 Dec 2025 07:00:00 GMT</pubDate>
<description>International Biotechnology Trust PLC has declared its first interim dividend for the year ending 31 August 2026, amounting to 15.64 pence per ordinary share. This dividend represents an annualised yield of 3.2% based on the closing share price of 974 pence on 11 December 2025. The ex-dividend date is 29 December 2025, with the record date on 30 December 2025 and payment scheduled for 23 January 2026. This distribution aligns with the company's policy of paying dividends equivalent to 4% of its </description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/result-of-agm-885</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/result-of-agm-885</guid>
<pubDate>Fri, 12 Dec 2025 17:49:00 GMT</pubDate>
<description>International Biotechnology Trust PLC announced the results of its Annual General Meeting held on December 12, 2025, where all resolutions were passed with significant shareholder support, including the approval of the dividend policy with 99.96% of votes for and the re-election of directors with over 99% approval for most. The company also received strong backing for appointing Johnston Carmichael LLP as auditors with 99.80% of votes for, and for the continuation of the company with 99.95% of v</description>
</item>
<item>
<title>Change of Auditors</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/change-of-auditors-6</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/change-of-auditors-6</guid>
<pubDate>Tue, 09 Dec 2025 11:23:00 GMT</pubDate>
<description>International Biotechnology Trust PLC has proposed the appointment of Johnston Carmichael LLP as its new auditor for the financial year ending 31 August 2026, following a competitive tender process. This change will see PricewaterhouseCoopers LLP, the company's auditor since 2007, step down at the conclusion of the 2025 Annual General Meeting on 12 December 2025. The decision aligns with regulatory requirements for auditor rotation and the need for a new tender by 2027 due to audit firm tenure l</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/total-voting-rights-660</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/total-voting-rights-660</guid>
<pubDate>Fri, 28 Nov 2025 17:19:00 GMT</pubDate>
<description>International Biotechnology Trust PLC has announced its issued share capital as of November 28, 2025, comprises 41,383,817 ordinary shares, with 9,480,983 shares held in treasury, resulting in a total of 31,902,834 voting rights. This figure serves as the denominator for shareholders to determine their notification obligations under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.
Disclaimer*</description>
</item>
<item>
<title>Annual Financial Report on NSM</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/annual-financial-report-on-nsm-8</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/annual-financial-report-on-nsm-8</guid>
<pubDate>Fri, 07 Nov 2025 07:00:00 GMT</pubDate>
<description>Annual Financial Report on NSM.</description>
</item>
<item>
<title>Results analysis from Kepler Trust Intelligence</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/results-analysis-from-kepler-trust-intelligence-32</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/results-analysis-from-kepler-trust-intelligence-32</guid>
<pubDate>Thu, 06 Nov 2025 16:49:00 GMT</pubDate>
<description>Results analysis from Kepler Trust Intelligence.</description>
</item>
<item>
<title>Investor Presentation via Investor Meet Company</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/investor-presentation-via-investor-meet-company-83</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/investor-presentation-via-investor-meet-company-83</guid>
<pubDate>Tue, 04 Nov 2025 10:00:00 GMT</pubDate>
<description>Investor Presentation via Investor Meet Company.</description>
</item>
<item>
<title>Novartis to acquire IBT portfolio company Avidity</title>
<link>https://6ix.com/company/international-biotechnology-trust-plc/news/novartis-to-acquire-ibt-portfolio-company-avidity</link>
<guid isPermaLink="true">https://6ix.com/company/international-biotechnology-trust-plc/news/novartis-to-acquire-ibt-portfolio-company-avidity</guid>
<pubDate>Mon, 27 Oct 2025 10:58:00 GMT</pubDate>
<description>International Biotechnology Trust PLC (IBT) announced that Avidity Biosciences, an IBT portfolio company, will be acquired by Novartis for $12 billion in cash. Avidity shareholders will receive $72.00 per share, a 46% premium over the closing share price on October 24th. As of October 23rd, Avidity represented 2.55% of IBT's Net Asset Value and was the eighth-largest holding in IBT's quoted portfolio. This acquisition marks IBT's ninth M&A transaction involving a portfolio holding this year and </description>
</item>
</channel>
</rss>